Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Simply Wealthy

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Oct 21, 2022 2:04pm

132 Views

Post# 35039572

RE:RE:RE:Simply Wealthy

Yes. I fully agree the Biohaven model is doable.

To digress, the SimplyWall Street thing is totally unrelated to these discussions. They seem to say ONC could run out of money. I was looking for comments on their assertion and am not overly concerned myself with Simply's opinion.

To digress even further, my collaboration idea is not at all likely, and if we get a deal, it is very likely along the lines of what you have been suggesting. Cheers

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario